

GENETIC TECHNOLOGIES LTD  
Form 424B3  
January 20, 2015

THE BANK OF NEW YORK MELLON

101 Barclay Street

New York, New York 10286

January 20, 2015

Securities & exchange Commission

450 Fifth Street, NW

Washington, DC 20549

Attn.: Document Control

RE: American Depositary Receipts representing thirty deposited shares of  
Genetic Technologies Limited.

(Form F-6, Registration No. 333-183861)

\*\*\*\*\*

Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the Securities Act of 1933, as amended, on behalf of The Bank of New York Mellon, as Depositary for securities against which American Depositary Receipts are to be issued, we attach a copy of the new prospectus ("Prospectus") reflecting the change in Ratio.

Edgar Filing: GENETIC TECHNOLOGIES LTD - Form 424B3

As required by Rule 424(e), the upper right hand corner of the Prospectus cover page has a reference to Rule 424(b)(3) and to the file number of the registration statement to which the Prospectus relates.

Pursuant to Section III B of the General Instructions to the Form F-6 Registration Statement, the Prospectus consists of the ADR certificate with the revised ratio for Genetic Technologies Limited.

The Prospectus has been revised to reflect the new ratio, which has been changed to read:

“Each American Depositary Share represents one hundred fifty deposited Shares”.

Please contact me with any questions or comments at 212 815-2187.

Victor Francis

Vice President

The Bank of New York Mellon - ADR Division

Encl.

CC: Paul Dudek, Esq. (Office of International Corporate Finance)